Diabetes Pharmacology
Select the best answer for each question. After submission you’ll see your score and explanations.
Question 1
Moderate
Case 1 (New diagnosis).
A 54-year-old man presents with polyuria and fatigue. BMI 35. BP 142/88. A1C 9.4%. eGFR 82. No known ASCVD, HF, or CKD.
What is the best initial pharmacologic strategy?
Start metformin (Glucophage) monotherapy
Start basal insulin glargine (Lantus/Basaglar/Semglee)
Start metformin (Glucophage) plus a GLP-1 RA semaglutide (Ozempic/Rybelsus)
Start glyburide (Diabeta/Glynase) monotherapy
Start empagliflozin (Jardiance) monotherapy
Question 2
Moderate
Case 1 (3 months later).
He is on maximally tolerated metformin (Glucophage) + semaglutide (Ozempic). A1C is 8.8%. He has no HF/CKD/ASCVD and wants the next step with the best weight profile.
Which option is best to add?
Glimepiride (Amaryl)
Pioglitazone (Actos)
Empagliflozin (Jardiance)
Sitagliptin (Januvia)
Acarbose (Precose)
Question 3
Hard
Case 1 (1 year later).
He develops symptomatic HFrEF (EF 35%). Current meds: metformin (Glucophage) + semaglutide (Ozempic) + empagliflozin (Jardiance). A1C is 7.9%.
Which diabetes medication class should be AVOIDED because it can worsen HF via fluid retention?
Thiazolidinedione: pioglitazone (Actos)
DPP-4 inhibitor: sitagliptin (Januvia)
GLP-1 RA: dulaglutide (Trulicity)
Biguanide: metformin (Glucophage)
SGLT2 inhibitor: dapagliflozin (Farxiga)
Question 4
Hard
Case 2 (CKD nuance).
A 62-year-old woman with T2DM and CKD has eGFR 28 mL/min/1.73m². A1C 8.1%.
She is taking metformin (Glucophage) 1000 mg twice daily.
What is the most appropriate metformin action today?
Continue current dose unchanged
Increase metformin dose for better control
Discontinue metformin due to low eGFR
Switch to glyburide (Diabeta) for renal safety
Add pioglitazone (Actos) and keep metformin unchanged
Question 5
Hard
Case 2 (after change).
Metformin was stopped. You start dapagliflozin (Farxiga). Three weeks later she presents with nausea and malaise.
Labs: glucose 210 mg/dL, anion gap 20, bicarbonate 16, serum ketones positive.
What is the most likely diagnosis?
Hyperosmolar hyperglycemic state (HHS)
Classic diabetic ketoacidosis (DKA) with severe hyperglycemia
Euglycemic/near-euglycemic DKA related to SGLT2 inhibitor
Metformin-associated lactic acidosis
Acute pancreatitis
Question 6
Hard
Case 2 (mechanism).
Which mechanism best explains SGLT2 inhibitor–associated euglycemic DKA?
Direct pancreatic beta-cell necrosis
Increased glucagon-to-insulin ratio promoting lipolysis/ketogenesis
Severe inhibition of intestinal carbohydrate absorption
Massive lactic acid overproduction in muscle
Complete blockade of ketone clearance by the kidney
Question 7
Moderate
Case 3 (catabolic hyperglycemia).
A 48-year-old man with T2DM presents with polyuria, polydipsia, weight loss. A1C 11.2%, fasting glucose 320 mg/dL.
What is the best initial pharmacologic move?
Add sitagliptin (Januvia) to metformin
Add semaglutide (Ozempic) only
Start basal insulin glargine (Lantus/Basaglar/Semglee)
Start pioglitazone (Actos)
Start acarbose (Precose)
Question 8
Moderate
Case 3 (titration).
You start insulin glargine (Lantus) 10 units nightly and continue metformin.
After 1 week, fasting glucose remains 190–220 mg/dL.
Best next adjustment?
Increase basal insulin gradually based on fasting glucose trend
Add correction-scale (sliding scale) insulin only
Stop metformin to reduce hypoglycemia risk
Switch to NPH (Humulin N) immediately without titration
Add glyburide (Diabeta)
Question 9
Hard
Case 3 (basal vs prandial).
After titration, fasting glucose averages 105–120 mg/dL, but 2-hour post-meal glucose runs 220–260 mg/dL; A1C remains 8.3%.
Best next step?
Further increase basal insulin dose
Add rapid-acting insulin lispro (Humalog) before the largest meal
Switch basal insulin to NPH twice daily
Stop basal insulin and use only rapid-acting insulin
Add pioglitazone (Actos) and avoid mealtime insulin
Question 10
Hard
Case 4 (hypoglycemia in CKD).
A 76-year-old man with T2DM and CKD stage 4 (eGFR 22) has syncope; EMS glucose is 48 mg/dL.
Meds: glyburide (Diabeta), metformin (Glucophage), lisinopril.
Which medication is the most likely cause?
Metformin (Glucophage)
Lisinopril (Prinivil/Zestril)
Glyburide (Diabeta/Glynase)
Acarbose (Precose)
Sitagliptin (Januvia)
Question 11
Hard
Case 4 (mechanism of risk).
Why is glyburide (Diabeta) especially dangerous in advanced CKD?
It is cleared only by dialysis, so it accumulates immediately
Reduced renal clearance prolongs active metabolites, causing prolonged hypoglycemia
It blocks glucagon receptors, preventing counter-regulation
It causes severe dehydration leading to syncope
It directly stimulates insulin antibodies
Question 12
Hard
Case 5 (abdominal pain on GLP-1).
A 59-year-old woman with T2DM and obesity started semaglutide (Ozempic) 8 weeks ago. She now has persistent severe epigastric pain radiating to the back with vomiting.
Most concerning diagnosis?
GERD
Acute pancreatitis
Acute appendicitis
Diverticulitis
Nephrolithiasis
Question 13
Hard
Case 5 (pharmacologic effect).
Which drug effect is most responsible for the common early GI intolerance of GLP-1 receptor agonists (e.g., semaglutide/Ozempic)?
Acceleration of gastric emptying
Delayed gastric emptying and central satiety signaling
Inhibition of bile acid reuptake
Blockade of intestinal lactase
Direct stimulation of the vagus nerve to increase appetite
Question 14
Hard
Case 6 (DKA sequencing).
A 23-year-old woman with type 1 diabetes presents with DKA. Glucose 480 mg/dL, pH 7.12, serum K 2.9 mEq/L.
What is the best immediate next step?
Start insulin infusion now
Give IV sodium bicarbonate now
Give IV potassium replacement before insulin
Give subcutaneous rapid-acting insulin only
Start metformin (Glucophage)
Question 15
Hard
Case 6 (threshold).
Insulin therapy in DKA should be delayed until serum potassium is at least:
2.5 mEq/L
3.0 mEq/L
3.3 mEq/L
4.0 mEq/L
5.0 mEq/L
Question 16
Moderate
A 60-year-old with T2DM and established ASCVD (prior MI) is controlled on metformin (Glucophage) but A1C is 7.8%. eGFR 70.
Which add-on has the strongest evidence for reducing major adverse cardiovascular events (MACE)?
Glipizide (Glucotrol)
Sitagliptin (Januvia)
Liraglutide (Victoza)
Acarbose (Precose)
Repaglinide (Prandin)
Question 17
Hard
A 66-year-old with T2DM and albuminuric CKD (UACR 900 mg/g) on ACE inhibitor has A1C 7.6%. eGFR 42.
Which diabetes medication is most specifically associated with slowing CKD progression independent of glycemic effects?
Dapagliflozin (Farxiga)
Glimepiride (Amaryl)
Pioglitazone (Actos)
Saxagliptin (Onglyza)
Acarbose (Precose)
Question 18
Hard
A patient on canagliflozin (Invokana) asks why you advise holding it before major surgery.
Most important reason?
Avoid perioperative lactic acidosis
Avoid perioperative euglycemic DKA
Avoid severe hypertension
Avoid serotonin syndrome
Avoid QT prolongation
Question 19
Moderate
A 58-year-old on metformin (Glucophage) is scheduled for a contrasted CT scan. eGFR 38.
Best medication plan?
Continue metformin without changes
Hold metformin around contrast and reassess renal function after
Double metformin dose for 48 hours
Switch to glyburide (Diabeta) for 1 week
Add pioglitazone (Actos) and continue metformin
Question 20
Hard
A patient on insulin glargine (Lantus) has fasting glucose at target but frequent nocturnal hypoglycemia.
Which basal insulin change most reduces nocturnal hypoglycemia risk?
Switch to NPH (Humulin N) at bedtime
Switch to insulin degludec (Tresiba)
Stop basal insulin entirely
Switch to regular insulin (Humulin R) at bedtime
Add glyburide (Diabeta)
Question 21
Moderate
A 45-year-old with T2DM on metformin adds tirzepatide (Mounjaro/Zepbound). Which statement best describes tirzepatide’s pharmacology?
Dual GIP and GLP-1 receptor agonist
Dual GLP-1 and DPP-4 inhibitor
SGLT1/SGLT2 dual inhibitor
PPAR-gamma agonist
Alpha-glucosidase inhibitor
Question 22
Hard
A patient with T2DM and gastroparesis needs additional glucose lowering. Which option is least likely to worsen gastroparesis symptoms?
Semaglutide (Ozempic)
Liraglutide (Victoza)
Dulaglutide (Trulicity)
Sitagliptin (Januvia)
Tirzepatide (Mounjaro)
Question 23
Moderate
A 71-year-old with T2DM has recurrent severe hypoglycemia on glipizide (Glucotrol). You want a replacement with minimal hypoglycemia risk and once-daily oral dosing.
Best choice?
Glyburide (Diabeta)
Sitagliptin (Januvia)
Repaglinide (Prandin)
NPH insulin (Humulin N)
Regular insulin (Humulin R)
Question 24
Hard
A 63-year-old with T2DM is on metformin (Glucophage) + sitagliptin (Januvia). You are considering adding a GLP-1 RA (Ozempic).
Which change is most appropriate?
Continue sitagliptin and add Ozempic for dual incretin synergy
Stop sitagliptin when starting Ozempic
Stop metformin when starting Ozempic
Replace Ozempic with acarbose (Precose)
Replace both with glyburide (Diabeta)
Question 25
Moderate
Which diabetes medication class is most likely to cause edema and weight gain via fluid retention and adipogenesis?
SGLT2 inhibitors (Jardiance/Farxiga)
GLP-1 RAs (Ozempic/Victoza)
TZDs (Actos)
DPP-4 inhibitors (Januvia)
Alpha-glucosidase inhibitors (Precose)
Question 26
Hard
A 57-year-old with T2DM and osteoporosis risk needs add-on therapy. Which class is most associated with increased fracture risk?
TZDs (Actos)
GLP-1 RAs (Trulicity)
DPP-4 inhibitors (Tradjenta)
Metformin (Glucophage)
Meglitinides (Prandin)
Question 27
Moderate
A patient starts empagliflozin (Jardiance) and returns with vulvovaginal itching and discharge.
Most likely adverse effect?
Nephrolithiasis
Genital mycotic infection
Acute hepatitis
C. difficile colitis
Pancreatitis
Question 28
Hard
A patient with type 1 diabetes asks if an SGLT2 inhibitor could help with glucose control.
Best response?
Yes—safe and standard of care in type 1
Yes—use only if A1C is >10%
No—higher risk of DKA makes routine use inappropriate
Yes—only with sulfonylurea co-therapy
No—because it causes severe hypoglycemia
Question 29
Moderate
A 33-year-old pregnant patient with pregestational diabetes needs glucose-lowering therapy.
Best pharmacologic choice?
Metformin (Glucophage) as sole therapy for all patients
Glyburide (Diabeta) as first-line for all patients
Insulin (e.g., NPH + rapid-acting analog)
Empagliflozin (Jardiance)
Pioglitazone (Actos)
Question 30
Hard
A patient with T2DM on high-dose prednisone for asthma has marked post-lunch and evening hyperglycemia with near-normal fasting glucose.
Which insulin strategy best targets steroid-induced hyperglycemia pattern?
Increase bedtime basal insulin only
Add or increase daytime NPH insulin (Humulin N) timed to steroid peak
Stop all insulin and start metformin
Use only sliding-scale insulin without basal
Switch to degludec (Tresiba) and avoid prandial insulin
Question 31
Moderate
Which insulin is best categorized as rapid-acting and typically used for mealtime coverage?
Insulin lispro (Humalog)
Insulin NPH (Humulin N)
Insulin glargine (Lantus)
Insulin detemir (Levemir)
Insulin degludec (Tresiba)
Question 32
Moderate
A patient on acarbose (Precose) develops symptomatic hypoglycemia after taking it with insulin.
Best treatment for hypoglycemia in this situation?
Sucrose (table sugar)
Oral glucose (dextrose) tablets/gel
High-fructose corn syrup
Lactose-containing milk
Acarbose extra dose
Question 33
Hard
A patient on insulin pump therapy presents with DKA after the infusion set dislodged.
Compared with long-acting basal injection regimens, pump failure leads to more rapid DKA because pumps deliver:
NPH insulin only
Long-acting insulin only
Rapid-acting insulin as basal without a long-acting depot
Regular insulin with a long half-life
Mixed insulin with protamine
Question 34
Moderate
A 64-year-old with T2DM and mild cognitive impairment needs a regimen with low hypoglycemia risk and simple dosing.
Which option is least appropriate?
Metformin (Glucophage)
Sitagliptin (Januvia)
Empagliflozin (Jardiance)
Glyburide (Diabeta)
Semaglutide (Ozempic)
Question 35
Hard
A patient with T2DM and prior pancreatitis needs add-on therapy.
Which option is most prudent to avoid due to pancreatitis concern?
Empagliflozin (Jardiance)
Pioglitazone (Actos)
Semaglutide (Ozempic)
Metformin (Glucophage)
Acarbose (Precose)
Question 36
Moderate
Which drug class is most likely to cause hypoglycemia independent of meal timing due to glucose-independent insulin release?
GLP-1 RAs (Victoza/Ozempic)
DPP-4 inhibitors (Januvia)
Sulfonylureas (Glucotrol/Amaryl/Diabeta)
SGLT2 inhibitors (Jardiance/Farxiga)
Alpha-glucosidase inhibitors (Precose)
Question 37
Hard
A patient with T2DM on basal-bolus insulin is started on semaglutide (Ozempic). Within 2 weeks, fasting glucose is frequently low.
Most appropriate insulin adjustment strategy?
Increase basal insulin to overcome GI side effects
Reduce basal insulin dose and reassess prandial needs
Stop Ozempic immediately in all cases
Switch prandial insulin to NPH
Add glyburide (Diabeta)
Question 38
Moderate
A patient with A1C 7.6% on metformin wants an oral add-on with minimal hypoglycemia and is concerned about UTIs/genital infections.
Best choice?
Empagliflozin (Jardiance)
Canagliflozin (Invokana)
Sitagliptin (Januvia)
Glyburide (Diabeta)
Repaglinide (Prandin)
Question 39
Hard
A patient with T2DM and severe hypertriglyceridemia presents with abdominal pain and elevated lipase.
Which diabetes medication should be held during evaluation because it can confound symptoms by causing significant GI effects?
Semaglutide (Ozempic)
Metformin (Glucophage)
Insulin glargine (Lantus)
Pioglitazone (Actos)
Sitagliptin (Januvia)
Question 40
Hard
A 56-year-old on saxagliptin (Onglyza) develops new HF symptoms; EF is reduced.
Which statement best reflects the evidence signal?
Saxagliptin is strongly protective against HF hospitalization
Saxagliptin has been associated with increased HF hospitalization risk in some outcome trials
All DPP-4 inhibitors reduce HF risk equally
DPP-4 inhibitors commonly cause DKA
DPP-4 inhibitors cause profound weight loss
Question 41
Moderate
A patient is on pioglitazone (Actos) and develops new edema and 8 lb weight gain.
Which additional finding would most strongly prompt discontinuation?
Mild nausea after meals
New dyspnea on exertion and orthopnea
Occasional constipation
Mild headache
Seasonal allergies
Question 42
Hard
A patient on basal insulin has been progressively uptitrated; now basal dose is very high and fasting glucose is only slightly above goal, but A1C remains elevated.
This pattern most strongly suggests:
Need for more basal insulin
Predominant postprandial hyperglycemia requiring prandial coverage
Insulin allergy
Metformin-induced hypoglycemia
Alpha-glucosidase deficiency
Question 43
Moderate
A 50-year-old with T2DM asks why GLP-1 RAs (Ozempic/Victoza/Trulicity) have low hypoglycemia risk when used alone.
Best explanation?
They block insulin release unless glucose is very low
They stimulate insulin secretion in a glucose-dependent manner
They replace insulin directly
They prevent hepatic glucose output completely
They cause constant urinary glucose loss
Question 44
Hard
A patient on insulin and acarbose (Precose) is hypoglycemic and only has a sucrose-containing beverage available.
What is most accurate?
Sucrose will correct hypoglycemia as quickly as glucose tablets
Sucrose correction may be delayed because acarbose blocks sucrose breakdown
Sucrose will worsen hypoglycemia by inhibiting insulin
Sucrose is contraindicated due to pancreatitis risk
Sucrose will cause immediate hyperkalemia
Question 45
Moderate
A 61-year-old with T2DM wants an agent that lowers A1C and also lowers systolic blood pressure modestly.
Best match?
SGLT2 inhibitor (Jardiance/Farxiga)
Sulfonylurea (Glucotrol)
TZD (Actos)
DPP-4 inhibitor (Januvia)
Meglitinide (Prandin)
Question 46
Hard
A patient with T2DM and recurrent UTIs is considering an SGLT2 inhibitor.
Which counseling point is most appropriate?
SGLT2 inhibitors eliminate UTI risk by sterilizing urine
They increase glycosuria and can raise risk of genital mycotic infections; UTI risk may increase in some patients
They cause immediate hypoglycemia regardless of other meds
They are contraindicated in anyone with hypertension
They are the only class that causes lactic acidosis
Question 47
Hard
A hospitalized patient with poor oral intake is taking home diabetes meds: metformin (Glucophage), empagliflozin (Jardiance), and glipizide (Glucotrol).
Which is most appropriate to hold immediately due to high inpatient hypoglycemia risk with reduced intake?
Metformin (Glucophage)
Empagliflozin (Jardiance)
Glipizide (Glucotrol)
All insulin
None; continue all meds
Question 48
Hard
A patient with T2DM is being discharged on basal insulin plus a GLP-1 RA. Which patient education point is most important to reduce hypoglycemia risk early?
Always double basal insulin on days you eat less
If fasting sugars run low, contact clinic to reduce basal insulin rather than skipping meals
Stop checking glucose once you start GLP-1 therapy
Take prandial insulin even if you skip meals
Use glyburide to prevent low sugars
Question 49
Moderate
Which medication is most likely to improve insulin sensitivity in adipose tissue and muscle (not insulin secretion)?
Glipizide (Glucotrol)
Pioglitazone (Actos)
Sitagliptin (Januvia)
Insulin lispro (Humalog)
Acarbose (Precose)
Question 50
Hard
A 55-year-old with T2DM and obesity is choosing between semaglutide (Ozempic) and sitagliptin (Januvia) as add-on to metformin.
Which statement is most accurate when comparing expected A1C and weight effects?
Januvia typically produces greater A1C reduction and more weight loss than Ozempic
Ozempic generally provides stronger A1C reduction and meaningful weight loss compared with Januvia
Both cause similar weight gain
Both have identical GI adverse effect profiles
Januvia has greater CV mortality benefit than Ozempic
Submit